Skip to main content
AVACTA GROUP PLC logo

AVACTA GROUP PLC — Investor Relations & Filings

Ticker · AVCT ISIN · GB00BYYW9G87 LEI · 2138009U3EG31OPMGH36 IL Manufacturing
Open in API
Filings indexed 708 across all filing types
Latest filing 2021-12-22 Regulatory Filings
Country GB United Kingdom
Listing IL AVCT

About AVACTA GROUP PLC

https://avacta.com/

Avacta Group PLC is a clinical-stage biotechnology company developing targeted oncology drugs. The company's core technology is the proprietary pre|CISION® platform, a drug delivery system designed to improve the safety and efficacy of potent cancer therapies. The platform works by linking a peptide to a cancer drug, rendering it inactive in the bloodstream. The drug is precisely activated only within the tumor microenvironment by the Fibroblast Activation Protein (FAP) enzyme, which is abundant in many solid tumors. This approach aims to concentrate the active therapy at the tumor site, thereby reducing systemic toxicity and improving the therapeutic window for patients. The company is advancing a pipeline of peptide drug conjugates (PDCs) based on this platform.

Recent filings

Filing Released Lang Actions
Price Monitoring Extension
Regulatory Filings Classification · 98% confidence The document is very short (1917 characters) and contains the header 'RNS Number : 5032W'. It announces a 'Price Monitoring Extension' related to trading procedures on the London Stock Exchange. It explicitly states that 'This information is provided by RNS, the news service of the London Stock Exchange' and is approved by the FCA as a Primary Information Provider. This structure—a brief, specific operational announcement distributed via the RNS system—fits best under the general Regulatory Filings category, as it is not a core financial report (like 10-K, IR, ER) nor a specific announcement like a dividend (DIV) or director dealing (DIRS). It is a miscellaneous regulatory notice.
2021-12-22 English
AffiDX Receives CE Mark for Consumer Self-Testing
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number' and is dated '22 December 2021'. It announces a specific corporate event: 'AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Receives CE Mark for Consumer Self-Testing'. This is a specific, material announcement released via the RNS system, which is the news service of the London Stock Exchange and an FCA Primary Information Provider. Since it is a specific, non-financial results announcement (like ER or IR) and not a general proxy/governance document, it fits best under the general regulatory announcement category, RNS, as it is a direct regulatory/material news release. It is not an Earnings Release (ER), Interim Report (IR), Annual Report (10-K), or a presentation (IP). It is a specific news update, making RNS the most appropriate general regulatory filing code.
2021-12-22 English
Issue of Equity and Total Voting Rights
Share Issue/Capital Change Classification · 99% confidence The document is identified by the header 'RNS Number : 8182V' and contains information about the 'Issue of Equity and Total Voting Rights' following the exercise of share options. This announcement details the issuance of 126,666 new ordinary shares and the resulting enlarged issued share capital. This type of corporate action, specifically related to changes in the number of shares outstanding, falls under the category of Share Issue/Capital Change (SHA). Although it is distributed via RNS, the specific content is about a share capital change, making SHA the most precise classification over the general RNS fallback.
2021-12-16 English
AffiDx® lateral flow test detects Omicron variant
Regulatory Filings Classification · 100% confidence The document begins with an 'RNS Number' and a date, indicating it is a regulatory announcement disseminated via the London Stock Exchange's news service (RNS). The content announces a specific operational update: that Avacta Group's AffiDx® SARS-CoV-2 antigen lateral flow test detects the Omicron variant. This is a material, non-periodic business update. It is not a full financial report (10-K, IR), a management discussion (MDA), or a formal earnings release (ER). Since it is a specific, material announcement distributed through the RNS system and doesn't fit the definitions for AGM-R, DVA, DIV, etc., the most appropriate classification is the general regulatory announcement category, RNS.
2021-12-15 English
Change of auditor
Regulatory Filings Classification · 98% confidence The document is identified by the RNS Number header and contains a formal announcement dated December 15, 2021. The core subject is the 'Change of auditor,' specifically announcing the appointment of BDO LLP and the resignation of KPMG LLP. This type of announcement, concerning corporate governance structure and key professional appointments (like auditors), falls under general corporate governance or management information. Since there is no specific category for 'Auditor Change,' and it relates to the structure and oversight of the company, it is best classified as Board/Management Information (MANG) or potentially Regulatory Filings (RNS) if it were purely a mandatory disclosure without significant context. However, the content details the Board's decision and includes commentary from the Audit Committee Chair, making MANG a strong fit. Given the context of regulatory reporting via RNS, and the nature of the change being a significant governance/administrative update, RNS is also a possibility, but MANG captures the substance better than the generic RNS fallback. Reviewing the definitions, MANG covers 'Announcement of changes in the company's board of directors or senior management.' While an auditor is not management or a director, the appointment/resignation of an auditor is a critical governance function overseen by the Board/Audit Committee, often grouped with management changes in filing systems. Since the document is a complete announcement and not just a notice that a report is attached (ruling out RPA), and it's not a full Annual Report (10-K) or Audit Report (AR), MANG is the most appropriate specific category for this governance-related change.
2021-12-15 English
FDA Approval of IND Application for AVA6000
Regulatory Filings Classification · 100% confidence The document begins with 'RNS Number : 8030T' and contains standard regulatory boilerplate language at the end, including references to the London Stock Exchange and the Financial Conduct Authority (FCA). The content is a press release announcing a significant corporate event: the FDA approval of an Investigational New Drug (IND) application for AVA6000, which enables expansion of a Phase I clinical trial into the US. This type of announcement, which is a formal regulatory disclosure disseminated via the RNS system, fits best under the general 'Regulatory Filings' category, as it is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a specific shareholder communication (DEF 14A, AGM-R). Since it is a general, time-sensitive regulatory announcement distributed through the official channel (RNS), RNS is the most appropriate classification.
2021-11-29 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.